# US 2025/0367137 A1 · Phloroglucinol Formulations And Methods Of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367137 A1
- Document ID: US20250367137A1
- Status: Published application
- Kind: A1
- Application number: 18/871,882
- Filed: 2023-06-13
- Published: 2025-12-04
- Earliest claimed: 2022-06-13
- Assignees: CinPhloro Pharma, LLC
- Applicants: CinPhloro Pharma, LLC
- Inventors: Mary BOND; Dalia LEVINE; Brian MURPHY; Jon ISAACSOHN; Piyush PATEL
- Web page: https://patentgrep.com/patent/US20250367137A1

## CPC

- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/167: {with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K9/5073)}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/501: {Inorganic compounds}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides pharmaceutical compositions comprising a total amount of about 50 mg to about 1000 mg of an active pharmaceutical ingredient (API) that is phloroglucinol, trimethylphloroglucinol, a pharmaceutically acceptable salt thereof, or a combination thereof. The pharmaceutical composition comprises an immediate release portion, a first modified release portion, and a second modified release portion. Also provided are oral dosage units comprising the pharmaceutical compositions and methods of treating a spasmodic condition in a subject in need thereof using the pharmaceutical compositions or oral dosage units.

## Claims

### Claim 1

A pharmaceutical composition comprising a total amount of about 50 mg to about 1000 mg of an active pharmaceutical ingredient (API) that is phloroglucinol, trimethylphloroglucinol, a pharmaceutically acceptable salt thereof, or a combination thereof, wherein the pharmaceutical composition comprises:
an immediate release portion comprising about 20 to about 40% by weight of the total amount of the API, wherein at least about 90% by weight of the API in the immediate release portion is released from the pharmaceutical composition within about 2 hours, as measured by the USP 2 paddle method at about 50 rpm in about 750 mL of an aqueous solution comprising about 0.1N HCl solution at about 37° C.;
a first modified release portion comprising about 20 to about 40% by weight of the total amount of the API, wherein at least about 90% by weight of the API in the first modified release portion is released from the pharmaceutical composition after at least about 2 hours to about 4 hours, as measured by the USP 2 paddle method at about 50 rpm in about 750 mL of an aqueous solution comprising about 0.1N HCl solution at about 37° C.; and
a second modified release portion comprising about 20 to about 40% by weight of the total amount of the API, wherein at least about 90% by weight of the API in the second modified release portion is released from the pharmaceutical composition after about 4 or more hours, as measured by the USP 2 paddle method at about 50 rpm in about 750 mL of an aqueous solution comprising about 0.1N HCl solution at about 37° C.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the API is phloroglucinol, trimethylphloroglucinol, or a pharmaceutically acceptable salt thereof.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, in the form of a plurality of beads or granules

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first modified release portion comprises an API-containing core coated with a first enteric polymer capable of dissolution at a pH of about 5.5.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the first enteric polymer is a methacrylic acid copolymer, such as a methacrylic acid ethyl acrylate copolymer, or such as a 1:1 methacrylic acid:ethyl acrylate copolymer, or such as a Eudragit® L 30 D-55 polymer.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the second modified release portion comprises an API-containing core coated with a second enteric polymer capable of dissolution at a pH of 6.8 or higher.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the enteric polymer is a methacrylic acid copolymer, such as a methacrylic acid, methyl acrylate, methyl methacrylate copolymer, or such as a Eudragit® FS 30D copolymer.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein;
the immediate release portion is coated onto the first modified release portion, or
the immediate release portion is coated onto the second modified release portion, or
the immediate release portion is coated onto a combination of the first release portion and the second release portion.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first modified release portion is coated onto the second release portion.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the immediate release portion is coated onto the first modified release portion.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein at least about 30% by weight of the total amount of API in the composition is released from the composition over a period of about 5 minutes to about 2 hours as measured by the USP 2 paddle method at about 50 rpm in about 750 mL of an aqueous solution comprising about 0.1N HCl solution at about 37° C.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein at least about 60% by weight of the total amount of the API in the composition is released from the pharmaceutical composition over a period of about 2 hours to about 4 hours as measured by the USP 2 paddle method at about 50 rpm in about 750 mL of an aqueous solution comprising about 0.1N HCl solution at about 37° C.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1, wherein at least about 80% by weight of the total amount of the API in the composition is released from the pharmaceutical composition over a period of about 3 hours to about 6 hours as measured by the USP 2 paddle method at about 50 rpm in about 750 mL of an aqueous solution comprising about 0.1N HCl solution at about 37° C.

### Claim 19 (depends on 1)

The pharmaceutical composition of claim 1, comprising:
about 50 mg to about 500 mg of the API in the immediate release portion, such as about 50 mg to about 400 mg, or such as about 160 mg.

### Claim 20 (depends on 1)

The pharmaceutical composition of claim 1, comprising about 25 mg to about 200 mg of the API in the first modified release portion, such as about 50 mg to about 200 mg, or such as about 160 mg, or such as about 80 mg.

### Claim 21 (depends on 1)

The pharmaceutical composition of claim 1, comprising about 25 mg to about 300 mg of the API in the second modified release portion, such as about 25 mg to about 200 mg, or such as about 160 mg, or such as about 80 mg.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

An oral dosage unit comprising the pharmaceutical composition of claim 1.

### Claim 24 (depends on 23)

The oral dosage unit of claim 23, comprising:
about 10 to about 60% by weight, based on the weight of the oral dosage unit, of the immediate release portion, or such as about 30 to about 50% by weight, or such as about 43% by weight; and/or
about 10 to about 40% by weight, based on the weight of the oral dosage unit, of the first modified release portion, or such as about 20 to about 30% by weight, or such as about 28% by weight; and/or
about 10 to about 40% by weight, based on the weight of the oral dosage unit, of the second modified release portion, or such as about 20 to about 30% by weight, or such as about 28% by weight.

### Claim at position 25

25-27. (canceled)

### Claim 28 (depends on 23)

A method of treating a spasmodic condition in a subject in need thereof, comprising orally administering to the subject, an oral dosage unit of claim 23, wherein the oral administration to the subject in a fed state results in
a median Tmax of the API of about 0.5 to about 1.75 hours;
a mean Cmax of the API of about 269 to about 1512 ng/ml;
a mean AUCtau of the API of about 879 to about 4695 h*ng/ml; and/or
a mean t½ of the API of about 1.6 hours to about 2.4 hours
or
wherein the oral administration to the subject in a fasted state results in
a median Tmax of the API of about 0.5 hours;
a mean Cmax of the API of about 2745 to about 4874 ng/mL;
a mean AUCtau of the API of about 4567 to about 6853 h*ng/mL; and/or
a mean t½ of the API of about 2 hours.

### Claim 29 (depends on 28)

The method of claim 28, wherein the spasmodic condition is a sudden involuntary muscle contraction of the bronchi, stomach, intestine, ureter, gall bladder, kidney, or bile duct; gallstones; a gastrointestinal disorder; inflammatory bowel syndrome; or renal colicky pain.

### Claim at position 28

30-39. (canceled)
